AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Morgan Stanley Initiates Coverage of COMPASS Pathways with Buy Rating
ByAinvest
Friday, Aug 8, 2025 9:38 pm ET1min read
Morgan Stanley analyst Judah Frommer initiated coverage of COMPASS Pathways (CMPS) with a Buy rating and a $10.00 price target. The analyst consensus on CMPS is a Strong Buy with an average price target of $15.10, representing a 239.33% upside. CMPS market cap is $408M and has a P/E ratio of -2.38.
Morgan Stanley (NYSE:MS) upgraded Novartis (NYSE:NVS) from Underweight to Equalweight on Friday, raising its price target to $100.00 from $91.00. The investment bank cited Novartis’s improved mid-term growth profile compared to its peer Roche, projecting 4% sales and EBIT growth for Novartis between 2025-2028 versus 3% for Roche. Morgan Stanley highlighted Novartis’s potential for upside surprises from better commercial execution on key growth drivers and a more promising catalyst path in the pharmaceutical sector. The firm expressed confidence in Novartis’s bolt-on M&A strategy focused on mid-size assets supporting its four key therapeutic areas, suggesting this approach is better positioned to address loss of exclusivity (LOE) challenges expected at the turn of the decade. While upgrading Novartis, Morgan Stanley maintained its preference for AstraZeneca (NASDAQ:AZN) among European large-cap pharmaceutical companies, citing its growth at a reasonable price and more manageable long-term LOE risk.Separately, Morgan Stanley analyst Judah Frommer initiated coverage of Compass Pathways (CMPS) with a Buy rating and a $10.00 price target. The analyst consensus on CMPS is a Strong Buy with an average price target of $15.10, representing a 239.33% upside. CMPS market cap is $408M and has a P/E ratio of -2.38. Compass Pathways is dedicated to accelerating patient access to evidence-based innovation in mental health. The company's Phase 3 TRD program is ongoing, with pivotal trials 1 (COMP005) and 2 (COMP006) showing promising results. The lead product candidate, COMP360 psilocybin treatment for treatment-resistant depression (TRD), has published Phase 2 data in The New England Journal of Medicine and reported Phase 2 PTSD positive top-line data in Q2 2024.
References:
[1] https://ng.investing.com/news/analyst-ratings/morgan-stanley-upgrades-novartis-stock-rating-to-equalweight-on-growth-profile-93CH-2051863
[2] https://www.marketscreener.com/news/compass-pathways-investor-presentation-august-2025-ce7c5edfd18ffe24
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet